Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express α-Gal epitopes: A novel approach to immunotherapy in pancreatic cancer

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5259-5269

  Deguchi, Takashi ^a   Tanemura, Masahiro ^a   Miyoshi, Eiji ^a   Nagano, Hiroaki ^a   Machida, Tomohiko ^a   Ohmura, Yoshiaki ^a   Kobayashi, Shogo ^a   Marubashi, Shigeru ^a   Eguchi, Hidetoshi ^a   Takeda, Yutaka ^a   Ito, Toshinori ^a   Mori, Masaki ^a   Doki, Yuichiro ^a   Sawa, Yoshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA GALACTOSIDASE; EPITOPE; MUCIN 1; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MELANOMA; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CANCER VACCINES; EPITOPES; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; MICE, KNOCKOUT; MUCIN-1; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PROTEIN ENGINEERING; SWINE; T-LYMPHOCYTES; TRANSFECTION; TRISACCHARIDES;

EID: 77954363486     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4313     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009;59:225-49.
2. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10-5.
3. Ueno H, Kosuge T, Matsuyama Y, et al, Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer. Br J Cancer 2009;101:908-15.
4. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-16.
5. Hinoda Y, Ikematsu Y, Horinochi M, et al. Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 2003;38:1162-6. (Pubitemid 38128828)
6. Taylor-Papadimitriou J, Burchell J, Miles DW. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-13.
7. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339-53.
8. Masaki Y, Oka M, Ogura Y, et al. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma. Hepatogastroenterology 1999;46:2240-5. (Pubitemid 29454075)
9. Schuman JT, Grinstead JS, Apostolopoulos V, Campbell AP. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen. Biopolymers 2005;77:107-20.
10. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6:955-64.
11. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12:869-77.
12. Rong Y, Jin D, Wu W, et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009;9:191.
13. Danielczyk A, Stahn R, Faulstich D, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55:1337-47.
14. Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res 2008;68:3450-7.
15. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
16. Galili U, Tibell A, Samuelsson B, Rydberg L, Groth CG. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995;59:1549-56.
17. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 1984;160:1519-31.
18. Davin JC, Malaise M, Foidart J, Mahieu P. Anti-α-galactosyl antibodies and immune complexes in children with Henoch-Schönlein purpura or IgA nephropathy. Kidney Int 1987;31:1132-9.
19. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988;56:1730-7.
20. Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 2007;178:4676-87.
21. Abdel-Motal UM, Wigglesworth K, Galili U. Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother 2009;58:1545-56.
22. Abdel-Motal UM, Wigglesworth K, Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 2009;27:3072-82.
23. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal α 1→3Gal epitope in primates. Proc Natl Acad Sci U S A 1987;84:1369-73.
24. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-62.
25. Galili U, Swanson K. Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci U S A 1991;88:7401-4.
26. Tanemura M, Yin D, Chong AS, Galili U. Differential immune responses to α-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest 2000;105:301-10.
27. Tanemura M, Saga A, Kawamoto K, et al. In vitro and in vivo prevention of human CD8+ CTL-mediated xenocytotoxicity by pig c-FLIP expression in porcine endothelial cells. Am J Transplant 2008;8:288-97.
28. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
29. LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 1999;59:3417-23.
30. Tanemura M, Ogawa H, Yin DP, Chen ZC, DiSesa VJ, Galili U. Elimination of anti-Gal B cells by α-Gal ricin1. Transplantation 2002;73:1859-68.
31. Yuan Z, Wong S, Borrelli A, Chung MA. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 2007;362:740-6.
32. Sipos B, Möser S, Kalthoff H, Török V, Löhr M, Klöppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003;442:444-52.
33. Gorelik E, Duty L, Anaraki F, Galili U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α 1,3 galactosyltransferase gene transfection. Cancer Res 1995;55:4168-73.
34. Ogawa H, Galili U. Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay. Glycoconj J 2006;23:663-74.
35. Galili U, LaTemple DC, Radic MZ. A sensitive assay for measuring α-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 1998;65:1129-32.
36. Mueller MT, Hermann PC, Witthauer J, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009;137:1102-13.
37. Ohdan H, Yang YG, Shimizu A, Swenson KG, Sykes M. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal α 1,3Gal-mediated graft rejection. J Clin Invest 1999;104:281-90.
38. Hosoi A, Takeda Y, Furuichi Y, et al. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization. Cancer Res 2008;68:3941-9.
39. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
40. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
41. Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997;18:281-5.
42. LaTemple DC, Galili U. Adult and neonatal anti-Gal response in knock-out mice for α1,3galactosyltransferase. Xenotransplantation 1998;5:191-6.
43. Thall AD, Malý P, Lowe JB. Oocyte Gal α 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 1995;270:21437-40.
44. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of α-galactosyl epitopes by recombinant α1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996;56:3069-74.
45. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995;55:4000-3.
46. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
47. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008;26:2806-12.
48. Huang P, Wang CY, Gou SM, et al. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 2008;14:3903-7.